Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed at $21.5 in the last session, up 0.09% from day before closing price of $21.48. In other words, the price has increased by $0.09 from its previous closing price. On the day, 1.83 million shares were traded. AVDL stock price reached its highest trading level at $21.6 during the session, while it also had its lowest trading level at $21.48.
Ratios:
We take a closer look at AVDL’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 57.17. For the most recent quarter (mrq), Quick Ratio is recorded 2.37 and its Current Ratio is at 2.76. In the meantime, Its Debt-to-Equity ratio is 0.38 whereas as Long-Term Debt/Eq ratio is at 0.37.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $16.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 2110256640 and an Enterprise Value of 2045419264. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.46 while its Price-to-Book (P/B) ratio in mrq is 21.28. Its current Enterprise Value per Revenue stands at 8.231 whereas that against EBITDA is 757.843.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.31, which has changed by 1.685 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $23.57, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 1.17%, while the 200-Day Moving Average is calculated to be 52.41%.
Shares Statistics:
According to the various share statistics, AVDL traded on average about 2.98M shares per day over the past 3-months and 1694010 shares per day over the past 10 days. A total of 97.23M shares are outstanding, with a floating share count of 91.46M. Insiders hold about 6.50% of the company’s shares, while institutions hold 88.55% stake in the company. Shares short for AVDL as of 1767139200 were 2730297 with a Short Ratio of 0.92, compared to 1764288000 on 3906360. Therefore, it implies a Short% of Shares Outstanding of 2730297 and a Short% of Float of 2.8099999.
Earnings Estimates
The firm’s stock currently is rated by 7.0 analysts. The consensus estimate for the next quarter is $0.13, with high estimates of $0.17 and low estimates of $0.08. Analysts are recommending an EPS of between $0.79 and $0.11 for the fiscal current year, implying an average EPS of $0.28. EPS for the following year is $0.78, with 8.0 analysts recommending between $1.14 and $0.58.
Revenue Estimates
According to 5 analysts,. The current quarter’s revenue is expected to be $80.3M. It ranges from a high estimate of $83M to a low estimate of $79.3M. As of. The current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.41MFor the next quarter, 5 analysts are estimating revenue of $80.07M. There is a high estimate of $87M for the next quarter, whereas the lowest estimate is $75M.
A total of 5 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $281.1M, while the lowest revenue estimate was $274.9M, resulting in an average revenue estimate of $277.73M. In the same quarter a year ago, actual revenue was $169.12MBased on 10 analysts’ estimates, the company’s revenue will be $359.06M in the next fiscal year. The high estimate is $378.3M and the low estimate is $345.1M.
